Vedolizumab
- Generic Name
- Vedolizumab
- Brand Names
- Entyvio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943609-66-3
- Unique Ingredient Identifier
- 9RV78Q2002
- Background
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative colitis or Crohn's disease. α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 intera...
- Indication
Vedolizumab is indicated for adult patients with moderately to severely active Ulcerative Colitis or Crohn’s disease.
- Associated Conditions
- Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 158
- Registration Number
- NCT04738942
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵Ieda Hospital, Toyota, Aichi, Japan
🇯🇵Hirosaki University Hospital, Hirosaki, Aomori, Japan
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04407247
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Pontifícia Universidade Católica do Paraná
- Target Recruit Count
- 100
- Registration Number
- NCT04362735
Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1096
- Registration Number
- NCT03824561
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Lung Non-Small Cell CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmPathologic Stage 0 Cutaneous Melanoma AJCC v8Pathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT03819296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 1
- Registration Number
- NCT03802214
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇨🇦University of Western Ontario, London, Ontario, Canada
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT03657160
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 20
- Registration Number
- NCT03629379
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT03558152
- Locations
- 🇵🇱
Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gda?sk, Poland
🇷🇸Clinical Hospital Center Zvezdara, Belgrade, Serbia
🇵🇱Klimed Marek Klimkiewicz, Piotrków Trybunalski, Poland
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 16
- Registration Number
- NCT03329209
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.